Trust Signals
Written by the FormBlends Medical Team. Reviewed against peer-reviewed literature and FDA labeling. No affiliate relationship with any HGH product vendor. All claims graded by evidence type below.Key Takeaways
- Native human growth hormone is exactly 191 amino acids long. The "191aa" label is a marketing term, not a distinct drug designation.
- The biologically critical features of authentic HGH are not its amino acid count but its two disulfide bonds (Cys53-Cys165 and Cys182-Cys189) and correct three-dimensional folding.
- Early bacterial HGH added an N-terminal methionine, producing a 192-residue molecule associated with higher antibody rates. That history is why "191aa" became a marketing claim at all.
- Gray-market "191aa" products cannot be verified as biologically equivalent without a cell-based potency assay on the specific vial you are using.
- Pharmaceutical somatropin (FDA-approved) has the strongest clinical evidence for GH deficiency and is the only form with regulatory-backed quality assurance.
Direct Answer
HGH 191aa and HGH refer to the same 191-amino-acid somatropin molecule. The "191aa" tag is marketing language, not a separate compound. The real distinction is manufacturing quality and regulatory status: pharmaceutical HGH is verified for potency, purity, and sterility; gray-market "191aa" products are not.Table of Contents
- What is HGH 191aa chemically?
- Why does the 191aa label exist at all?
- Evidence ledger: what the research actually shows
- Mechanism with numbers: how HGH works at the receptor
- What most pages get wrong about HGH 191aa
- The chemistry behind storage and stability rules
- Honest head-to-head: pharmaceutical HGH vs HGH 191aa vs secretagogues
- Operational and label literacy: how to read a COA
- Legal and regulatory status
- FAQ
- Sources
What Is HGH 191aa Chemically?
Human growth hormone (somatropin) is a 191-amino-acid single-chain polypeptide with a molecular weight of approximately 22 kilodaltons for the predominant isoform. It has four alpha helices and two internal disulfide bonds: a large loop connecting Cys53 to Cys165, and a small loop connecting Cys182 to Cys189. Both bonds are required for the correct tertiary structure that allows binding to the growth hormone receptor (GHR).
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →The pituitary also secretes smaller isoforms (notably a 20 kDa variant lacking amino acids 32 to 46), but the 22 kDa, 191-residue form is the dominant circulating species and the one replicated by recombinant manufacturing.
"HGH 191aa" is simply this same molecule described by its amino acid count. There is no pharmacopeial, FDA, or WHO designation that distinguishes "191aa HGH" from "HGH." The term exists primarily in gray-market vendor copy.
Why Does the 191aa Label Exist at All?
The history is real and worth knowing. First-generation recombinant HGH produced in E. coli expression systems could not cleave an initiator methionine from the N-terminus, producing a 192-residue molecule called met-HGH (methionyl-HGH). Protropin (somatrem, Genentech), approved in 1985, was this 192-residue form. Clinical studies found that met-HGH induced anti-GH antibodies in a meaningful proportion of treated children, though these antibodies rarely blocked efficacy. Subsequent manufacturing advances allowed production of authentic 191-residue somatropin (Humatrope, Genotropin, and others), which showed lower antibody formation.
Gray-market vendors began labeling their products "191aa" to signal they were selling the native-sequence form, not the older met-HGH. The label became a quality claim in vendor marketing. It does not, by itself, verify sequence accuracy, folding, or potency.
Evidence Ledger: What the Research Actually Shows
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Pharmaceutical somatropin improves height velocity in pediatric GH deficiency | Multiple large RCTs, meta-analyses | Strong positive | High |
| Pharmaceutical somatropin improves body composition in adult GHD | RCTs (e.g., Johannsson et al. JCEM) | Positive for lean mass, fat reduction | High |
| Met-HGH (192aa) increases anti-GH antibody rates vs 191aa | Controlled clinical comparisons, 1980s-1990s literature | Higher antibody rate with met-HGH | Moderate |
| Gray-market "HGH 191aa" products contain correctly folded, potent somatropin | No published RCTs; limited independent assay data | Unknown, variable | Very Low |
| HGH improves body composition in healthy, non-GHD adults | RCTs (e.g., Rudman et al. NEJM 1990, subsequent meta-analyses) | Modest positive for lean mass; does not improve strength or function reliably | Moderate (effect size small, adverse event profile significant) |
| HGH extends lifespan or reverses aging in humans | Mechanism and animal data only; no human RCT | Not established | Very Low |
| Disulfide bond integrity is required for GHR binding activity | In vitro structural and biochemical studies | Positive (loss of activity when bonds disrupted) | High (mechanistic) |
Mechanism With Numbers: How HGH Works at the Receptor
HGH binds sequentially to two GHR molecules to form a 1:2 ligand-receptor complex. Site 1 on HGH binds the first GHR with a dissociation constant in the low nanomolar range; Site 2 then recruits the second receptor. This dimerization activates JAK2 kinase, which phosphorylates STAT5b, driving transcription of IGF-1 and other downstream genes in the liver and peripheral tissues.
Circulating IGF-1 mediates many of the anabolic effects (protein synthesis, lipolysis in adipose tissue, longitudinal bone growth via growth plates). Pharmaceutical somatropin's subcutaneous half-life is roughly 2 to 4 hours, which is why protocols typically use daily injections to approximate the pulsatile overnight GH surge seen physiologically.
What this mechanism does NOT prove: a product labeled "191aa" that has lost disulfide bond integrity through heat or mishandling will present the correct sequence but fail to dimerize GHR properly, producing little or no IGF-1 response. Sequence identity does not equal biological activity.
What Most Pages Get Wrong About HGH 191aa
This is the section commodity blogs skip entirely.
The folding problem is bigger than the sequence problem. Nearly every gray-market vendor discussion focuses on "do we have 191 or 192 amino acids?" That is the wrong question for modern products. Today's primary risk is not a wrong amino acid count. It is whether the protein was correctly folded during refolding after bacterial fermentation. Proteins expressed at high density in E. coli often misfold into inclusion bodies. Refolding them into the correct three-dimensional structure is technically demanding. A product can pass a mass-spec check for molecular weight and still be mostly inactive misfolded aggregate.
Purity percentages on COAs are not potency data. A COA showing "99% purity by HPLC" tells you there is not much visible contamination by other proteins. It does not tell you whether the 99% that is "pure" HGH is biologically active. Only a cell-based bioassay (measuring IGF-1 secretion or GHR phosphorylation in a cell line) answers that question. Such assays are expensive and rarely included in gray-market COAs.
Endotoxin is the most common acute hazard. Bacterial fermentation produces lipopolysaccharide (endotoxin). Pharmaceutical manufacturing includes validated depyrogenation steps and LAL (Limulus Amebocyte Lysate) endotoxin testing. Gray-market products have no verified equivalent. Endotoxin in an injectable causes fever, chills, and in high doses, septic-shock-like responses.
IU vs mg dosing confusion is common. Somatropin potency is often labeled in International Units. The WHO standard establishes that 1 mg of somatropin is approximately 3 IU, though this varies slightly by bioassay lot. Some gray-market kits report only milligrams; others only IU. Without knowing the conversion and verifying it with a potency assay, actual dose is uncertain.
The Chemistry Behind Storage and Stability Rules
Lyophilized (freeze-dried) somatropin powder is relatively stable because removing water slows most degradation pathways. The relevant degradation routes for HGH are:
Deamidation: Asparagine residues, particularly at positions that are solvent-exposed, can lose an amide group under aqueous conditions or at elevated temperatures, converting asparagine to aspartate. This changes the local charge and can reduce receptor affinity. Deamidation accelerates with heat and alkaline pH.
Oxidation: Methionine residues (Met14 and Met125 in HGH) are susceptible to oxidation, especially in the presence of peroxides or metal ions. This is why reconstitution with bacteriostatic water (which contains benzyl alcohol, not a peroxide source) is preferred over using plain sterile water left in contact with air for extended periods. Oxidized HGH retains some activity but at reduced levels.
Aggregation: Shaking or vortexing reconstituted HGH creates air-water interfaces where the protein can unfold and form insoluble aggregates. This is why the standard instruction is to swirl gently, not shake. Once aggregates form, they cannot be reversed by refrigeration. Aggregated protein is both less active and potentially immunogenic.
Practical rules that follow from this chemistry: Store lyophilized vials at 2 to 8 degrees Celsius. Once reconstituted, keep refrigerated and use within the timeframe specified by the manufacturer (generally a few weeks for bacteriostatic water preparations). Never freeze reconstituted solution; freezing promotes aggregation. Never shake. Do not leave reconstituted vials at room temperature for hours before injection.
Honest Head-to-Head: Pharmaceutical HGH vs HGH 191aa vs Secretagogues
| Feature | Pharmaceutical Somatropin (FDA-approved) | Gray-market "HGH 191aa" | GH Secretagogues (e.g., Sermorelin, Ipamorelin) |
|---|---|---|---|
| Primary sequence | 191aa, verified | Claims 191aa, unverified independently | Different molecules entirely (GHRH analogs, GHRPs) |
| Folding and potency verified | Yes, cell-based assay required by USP | Rarely; COA typically shows purity only | Simpler peptides; synthetic purity verifiable by HPLC |
| Endotoxin testing | Mandatory per FDA/USP | Variable, often not disclosed | Variable by source |
| Clinical evidence base | High (multiple large RCTs) | None specific to gray-market products | Low to Moderate; sermorelin has approved history for pediatric GHD; ipamorelin mostly small studies |
| Preserves pulsatile GH secretion | No; suppresses endogenous GH via negative feedback | No | Yes; stimulates endogenous release |
| Legal status (US) | Prescription drug, legal with valid Rx | Prescription drug; gray-market sale is illegal | Varies; sermorelin is prescription; some GHRPs in legal gray area |
| Cost | High (hundreds to thousands USD/month) | Lower; reflects unverified quality | Lower than HGH; variable |
| Where the peptide LOSES | Cost; requires cold-chain; suppresses axis | Loses on every quality and safety dimension vs pharmaceutical | Less direct evidence for GHD treatment; indirect mechanism |
Operational and Label Literacy: How to Read a COA for HGH
Whether you are a clinician reviewing a compounded preparation or a researcher assessing a research-use product, the following checklist applies.
Molecular weight by mass spectrometry: Authentic somatropin should show a dominant peak at approximately 22,124 Daltons (the 22 kDa isoform). A peak at roughly 20 kDa indicates the 20 kDa isoform. A peak shifted higher may indicate oxidation adducts or sequence errors. A COA that reports only purity without an MS trace is insufficient for identity confirmation.
HPLC purity: Size-exclusion HPLC separates monomer from dimer and aggregates. Reverse-phase HPLC separates by hydrophobicity and can flag oxidized variants. Look for both. A purity of 95% or higher by SEC-HPLC is a minimum reasonable threshold, but this alone does not confirm activity.
Bioassay or potency data: The USP somatropin monograph requires a cell-based or in vivo potency assay. For pharmaceutical products, this is reported as units per vial or mg. For any injectable you are evaluating, ask: is there a bioassay result? If not, potency is unknown.
Endotoxin: Should be reported as Endotoxin Units per mg (EU/mg). For injectable use, USP limits are typically less than 5 EU/kg body weight per dose. A COA without endotoxin data is a red flag for any injectable product.
IU to mg conversion: Approximately 3 IU per mg by current WHO standard, but verify against the specific product's stated conversion because historical vials sometimes used older standards.
Reconstitution math example: A 10 IU vial reconstituted with 1 mL bacteriostatic water gives 10 IU/mL. A 3.3 IU dose requires 0.33 mL (33 units on a U100 insulin syringe). Always confirm the volume you are drawing matches the vial's stated concentration.
Legal and Regulatory Status
In the United States, somatropin is classified as a prescription drug under the Food, Drug, and Cosmetic Act. The Anabolic Steroid Control Act does not cover HGH, but the FD&C Act separately restricts its distribution. Selling or purchasing HGH without a valid prescription, or for purposes not approved by the FDA (which does not include general anti-aging or athletic performance), is a federal offense.
The "191aa" descriptor does not create a separate regulatory category. Any product containing somatropin, regardless of marketing name, is subject to the same legal constraints as FDA-approved Humatrope or Genotropin.
FAQ
Sources
- Rudman D, et al. "Effects of Human Growth Hormone in Men over 60 Years Old." New England Journal of Medicine. 1990;323(1):1-6.
- Johannsson G, et al. "Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure." Journal of Clinical Endocrinology and Metabolism. 1997;82(3):727-34.
- de Boer H, Blok GJ, Van der Veen EA. "Clinical aspects of growth hormone deficiency in adults." Endocrine Reviews. 1995;16(1):63-86.
- FDA. "Humatrope (somatropin) Prescribing Information." Eli Lilly. Available via FDA.gov Drugs@FDA database.
- FDA. "Genotropin (somatropin) Prescribing Information." Pfizer. Available via FDA.gov Drugs@FDA database.
- Baumann G. "Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins." Endocrine Reviews. 1991;12(4):424-49.
- Cunningham BC, Wells JA. "Comparison of a structural and a functional epitope." Journal of Molecular Biology. 1993;234(3):554-63. (GHR binding site 1 and 2 characterization)
- United States Pharmacopeia. Somatropin Monograph. USP-NF. Current edition.
- Chung CS, et al. "Immunogenicity of recombinant-DNA-derived versus pituitary-extracted human growth hormone." Hormone Research. 1990;33 Suppl 4:S1-5.
- FDA Center for Drug Evaluation and Research. "Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products." 2014.
- Liu DT, et al. "Deamidation of asparagine residues in recombinant human growth hormone." Pharmaceutical Research. 1991;8(12):1461-6.
- Becker GW, et al. "Oxidation of methionine residues in recombinant human alpha-1-antitrypsin: effects on biological activity and structure." Biochemistry. 1990;29(41):9745-52. (Mechanistic analog for methionine oxidation in therapeutic proteins)